Recent Finacing
Recent Raise
Tivorsan Pharmaceuticals develops GAG‑free recombinant human Biglycan (rhBGN) therapeutics that upregulate utrophin and nNOS and modulate MuSK for Duchenne muscular dystrophy, advancing preclinical to IND/Phase 1.
Focus Areas
Total Raised
Funding round